Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta-analysis.

IF 2.7 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Reproductive Medicine and Biology Pub Date : 2024-03-25 eCollection Date: 2024-01-01 DOI:10.1002/rmb2.12573

Shinnosuke Komiya, Jun Watanabe, Takero Terayama, Kyosuke Kamijo, Hidetaka Okada

{"title":"Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta-analysis.","authors":"Shinnosuke Komiya, Jun Watanabe, Takero Terayama, Kyosuke Kamijo, Hidetaka Okada","doi":"10.1002/rmb2.12573","DOIUrl":null,"url":null,"abstract":"Background: Follitropin δ may be an alternative to conventional follitropin α/β for controlled ovarian stimulation (COS) within assisted reproductive treatment (ART), but its efficacy and safety remain unknown. We performed a random-effects meta-analysis to compare the efficacy and safety of follitropin δ and follitropin α/β.Methods: We searched randomized controlled trials comparing follitropin δ and follitropin α/β using MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and WHO-ITCRP on December 14, 2022. The primary outcomes were the live birth rate and the incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS). The certainty of the evidence was assessed using the grading of recommendations assessment, development, and evaluation approach. The protocol was registered on the Open Science Framework.Results: Three studies involving 2682 participants were included in our meta-analysis. The results indicated that follitropin δ may result in little to no difference in live birth rates (risk ratio [RR], 1.12; 95% confidence interval [CI], 0.91-1.38; low certainty) and the incidence of moderate or severe OHSS (RR, 0.78; 95% CI, 0.48-1.26; low certainty) compared with follitropin α/β.Conclusion: Follitropin δ may result in little to no difference in COS compared with follitropin α/β, especially in terms of live births and safety.","PeriodicalId":21116,"journal":{"name":"Reproductive Medicine and Biology","volume":"23 1","pages":"e12573"},"PeriodicalIF":2.7000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961712/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Medicine and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/rmb2.12573","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Follitropin δ may be an alternative to conventional follitropin α/β for controlled ovarian stimulation (COS) within assisted reproductive treatment (ART), but its efficacy and safety remain unknown. We performed a random-effects meta-analysis to compare the efficacy and safety of follitropin δ and follitropin α/β.

Methods: We searched randomized controlled trials comparing follitropin δ and follitropin α/β using MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and WHO-ITCRP on December 14, 2022. The primary outcomes were the live birth rate and the incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS). The certainty of the evidence was assessed using the grading of recommendations assessment, development, and evaluation approach. The protocol was registered on the Open Science Framework.

Results: Three studies involving 2682 participants were included in our meta-analysis. The results indicated that follitropin δ may result in little to no difference in live birth rates (risk ratio [RR], 1.12; 95% confidence interval [CI], 0.91-1.38; low certainty) and the incidence of moderate or severe OHSS (RR, 0.78; 95% CI, 0.48-1.26; low certainty) compared with follitropin α/β.

Conclusion: Follitropin δ may result in little to no difference in COS compared with follitropin α/β, especially in terms of live births and safety.

查看原文本刊更多论文

在不孕症治疗中，follitropin delta 与 follitropin alpha/beta 的疗效和安全性对比：系统回顾与荟萃分析。

背景在辅助生殖治疗（ART）中，促性腺激素δ可替代传统的促性腺激素α/β用于控制性卵巢刺激（COS），但其有效性和安全性仍然未知。我们进行了随机效应荟萃分析，比较了促性腺激素δ和促性腺激素α/β的疗效和安全性：2022年12月14日，我们使用MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和WHO-ITCRP检索了比较促性腺激素δ和促性腺激素α/β的随机对照试验。主要结果是活产率和中度或重度卵巢过度刺激综合征（OHSS）的发生率。证据的确定性采用建议分级评估、制定和评价方法进行评估。研究方案已在开放科学框架（Open Science Framework）上注册：我们的荟萃分析纳入了三项研究，涉及 2682 名参与者。结果表明，与促性腺激素α/β相比，促性腺激素δ在活产率（风险比[RR]，1.12；95% 置信区间[CI]，0.91-1.38；低确定性）和中度或重度OHSS发生率（RR，0.78；95% CI，0.48-1.26；低确定性）方面几乎没有差异：结论：与促卵泡激素α/β相比，促卵泡激素δ可能导致的COS差异很小甚至没有差异，尤其是在活产率和安全性方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reproductive Medicine and Biology Multiple-

CiteScore

5.70

自引率

5.90%

发文量

审稿时长

20 weeks

期刊介绍： Reproductive Medicine and Biology (RMB) is the official English journal of the Japan Society for Reproductive Medicine, the Japan Society of Fertilization and Implantation, the Japan Society of Andrology, and publishes original research articles that report new findings or concepts in all aspects of reproductive phenomena in all kinds of mammals. Papers in any of the following fields will be considered: andrology, endocrinology, oncology, immunology, genetics, function of gonads and genital tracts, erectile dysfunction, gametogenesis, function of accessory sex organs, fertilization, embryogenesis, embryo manipulation, pregnancy, implantation, ontogenesis, infectious disease, contraception, etc.